Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

MRK Merck and Co Inc

98,06

-2,64 (-2,62%)

17 Jan 2025 - Fechado

Atrasado em 15 minutos

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

Both Shuttle Pharmaceuticals (Nasdaq:SHPH) and Northwest Biotherapeutics

To read the full story on AllPennyStocks.com, click here.

Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Merck.

Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Merck.

Notícias Merck and Co Inc

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
Quinta, 16 de Janeiro de 2025 (2 dias atrás) • Business Wire

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments
Segunda, 13 de Janeiro de 2025 (5 dias atrás) • AllPennyStocks.com

Merck’s GARDASIL® Receives Expanded Approval for Males in China
Quarta, 8 de Janeiro de 2025 (1 semana atrás) • Business Wire

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Segunda, 6 de Janeiro de 2025 (2 semanas atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Sexta, 3 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Segunda, 23 de Dezembro de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
Sexta, 20 de Dezembro de 2024 (4 semanas atrás) • Business Wire

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
Quinta, 19 de Dezembro de 2024 (4 semanas atrás) • Business Wire

Mais Notícias de Merck and Co Inc

Índice Bovespa

Fundo Invest Amazonia Fi...

Automob Participacoes ON

PARANAPANEMA ON

HBR Realty Empreendiment... ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições